Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Sir Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that meeting with the representatives of Investors/Analysts are scheduled with the Management of the Company, as per annexure. Please note that, no Unpublished Price Sensitive Information is proposed to be shared, thereat. Please also note that the schedule of the aforesaid meeting, is subject to change due to any exigencies on the part of Investors/Company. Thank You
17-06-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Sir Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that meeting with the representatives of Investors/Analysts are scheduled with the Management of the Company, as per annexure. Please note that, no Unpublished Price Sensitive Information is proposed to be shared, thereat. Please also note that the schedule of the aforesaid meeting, is subject to change due to any exigencies on the part of Investors/Company. Kindly take the above on record.
17-06-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that meeting with the representative of below Investor/Analyst is scheduled with the Management of the Company, as per the details attached. Please note that, no Unpublished Price Sensitive Information is proposed to be shared, thereat. Kindly take the above on record
07-06-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Sir Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Earnings Conference Call held on Monday, May 29, 2023, hosted by Motilal Oswal, for the Quarter & Financial Year ended March 31, 2023 is enclosed herewith. Thank You
03-06-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that meeting with the representatives of following Investors/Analysts are scheduled with the Management of the Company, as per the details mentioned in PDF Intimation File.
02-06-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that meeting with the representatives of following Investors/Analysts are scheduled with the Management of the Company, as per the details mentioned in PDF Intimation File.
02-06-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that meeting with the representatives of following Investors/Analysts are scheduled with the Management of the Company, as per the details mentioned in the PDF Intimation File.
02-06-2023
Bigul

Global Health Ltd (Medanta) Results Earnings Call for Q4FY23

 Conference Call with Global Health Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
29-05-2023
Bigul

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Dear Sir(s), Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the below link of Audio recording of Earnings Conference Call held on Monday, May 29, 2023 hosted by Motilal Oswal , for the Quarter & Financial Year ended March 31, 2023: https://d3b6u46udi9ohd.cloudfront.net/wp-content/uploads/2023/02/29140404/Medanta-Earnings-Call-Audio-Q4-FY23.mp3 This is for your information and record.
29-05-2023
Bigul

Q4FY23 Quarterly & FY23 Annual Result Announced for Global Health Ltd.

 Healthcare Facilities company Global Health announced Q4FY23 & FY23 results: Q4FY23: Highest ever quarterly total income of Rs 7,318 million; growth of 37.3% YoY EBITDA of Rs 1,915 million; growth of 107.9% YoY; margins improved to 26.2% Profit after tax of Rs 1,011 million; growth of 477.7% YoY 126 new beds added at Medanta Lucknow Occupied bed days increased by 25.6% YoY, representing an occupancy of 58% on increased bed capacity ARPOB grew by 7.5% to Rs 60,880; In-patient count increased by 32.4% YoY; Out-patient count increased by 25.6% YoY FY23: Total income of Rs 27,592 million; growth of 25.1% YoY EBITDA of Rs 6,771 million; growth of 38.3% YoY EBITDA margins improved from 22.2 % in FY22 to 24.5% in FY23 Profit after tax of Rs 3,261 million; growth of 66.2% YoY Net cash surplus of Rs 4,692 Strong operating cash flow with robust EBITDA to cash flow conversion of 95% ARPOB grew by 8.3% to 59,098; In-patient volume increased by 32.0%; Out-patient volume increased by 15.4% Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 18% in FY22 to 27% in FY23 amounting to Rs 7,426 million. EBITDA share increased from 16% in FY22 to 32% in FY23 amounting to Rs 2,159 million Medanta Patna which commenced IPD operations in January 2022 delivered revenue of Rs 1,707 million in FY23 and achieved EBITDA break even in its first full year of operations Revenue from international patients increased by 68% to Rs 1,564 million Outpatient pharmacy business continues to register strong growth. Revenue increased by 58% from Rs 536 million in FY22 to Rs 850 million in FY23 Commenting on FY23 and Q4FY23 results, Pankaj Sahni, Group CEO and Director said: “We are pleased to report that we continue to deliver on our strategy of sustainable and steady growth. For the year and quarter ending March 31, 2023, we have registered significant growth and strong financial performance across all revenue and profitability metrics. Medanta Patna is the latest unit of the Group that has delivered EBITDA breakeven in its first full year of operations. We continue our planned growth in beds and infrastructure, and remain an attractive destination for leading clinical talent which is highlighted by the addition of over 150 senior clinicians in the last fiscal year across the Group. Significant accomplishments of our clinical teams have been internationally recognized by Newsweek for the fourth consecutive year with Medanta Gurugram ranking as the 'Best Private Hospital’ in India'.” Result PDF
29-05-2023
Next Page
Close

Let's Open Free Demat Account